The human tolerability results
A reassuring comparison deserves attention. So do the people, route and exposure periods behind it.
The trial programme
The 2013 report on AOD9604 safety and tolerability covered roughly six trials totalling about 900 obese subjects. The route was oral, and durations across the studies ranged from 7 days to 24 weeks.
The authors reported a safety and tolerability profile indistinguishable from placebo and an absence of the adverse effects associated with full-length human growth hormone. That is a substantive observation from the trial programme. For me, that observed comparison carries more weight than the idea that a small fragment ought to be gentle.
Its boundaries are also quite tangible: the participants were obese adults, the administrations were oral, and the studies had those exposure periods. Changing any of those features changes the question being asked.
Oral exposure and placebo
My discomfort starts where ‘safe’ is allowed to cover more than the resemblance to placebo within trials. A tolerability comparison within trials can be useful without settling every possible risk of a substance. I cannot extend these observations indefinitely or apply them to a different route by enthusiasm alone.
I also separate tolerability from weight-loss benefit. They ask different things of a trial: what happened to participants during exposure, and whether a treatment produced the intended outcome. The tolerability finding reported here answers the former question within the programme’s scope.
This matters to the original attraction of a simpler peptide. A smaller molecular fragment can be an appealing design idea. The human comparison is where that appeal has to submit to observation.
A later safety review
A 2026 sports-medicine review included AOD-9604 among unapproved compounds. Across the wider peptide field it discussed, the review warned that rigorous human safety data were scarce and that serious harm was possible. That broader caution accompanies, rather than erases, the earlier oral tolerability report.
In my preferred follow-up, route, exposure and participants would be specified with the same care. Until then, ‘well tolerated in these trials’ is a useful statement to preserve at its original size. It gives the reassuring finding a place without asking it to answer every question.